Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2011 (2011), Article ID 609202, 10 pages
http://dx.doi.org/10.1155/2011/609202
Review Article

Vascular Pathology and Blood-Brain Barrier Disruption in Cognitive and Psychiatric Complications of Type 2 Diabetes Mellitus

1Department of Physiology and Neurobiology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
2Department of Ophthalmology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel
3Department of Psychiatry, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel

Received 20 October 2010; Accepted 28 December 2010

Academic Editor: Daniela Kaufer

Copyright © 2011 Yonatan Serlin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Stumvoll, B. J. Goldstein, and T. W. Van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” Lancet, vol. 365, no. 9467, pp. 1333–1346, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. T. Pirttila, R. Jarvenpaa, P. Laippala, and H. Frey, “Brain atrophy on computerized axial tomography scans: interaction of age, diabetes and general morbidity,” Gerontology, vol. 38, no. 5, pp. 285–291, 1992. View at Google Scholar · View at Scopus
  3. Y. Araki, M. Nomura, H. Tanaka et al., “MRI of the brain in diabetes mellitus,” Neuroradiology, vol. 36, no. 2, pp. 101–103, 1994. View at Google Scholar · View at Scopus
  4. T. Den Heijer, S. E. Vermeer, E. J. Van Dijk et al., “Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI,” Diabetologia, vol. 46, no. 12, pp. 1604–1610, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. B. Van Harten, F. E. De Leeuw, H. C. Weinstein, P. Scheltens, and G. J. Biessels, “Brain imaging in patients with diabetes: a systematic review,” Diabetes Care, vol. 29, no. 11, pp. 2539–2548, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. M. Gold, I. Dziobek, V. Sweat et al., “Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes,” Diabetologia, vol. 50, no. 4, pp. 711–719, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. P. L. Yau, D. C. Javier, C. M. Ryan et al., “Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus,” Diabetologia, vol. 53, no. 11, pp. 2298–2306, 2010. View at Publisher · View at Google Scholar · View at PubMed
  8. A. M. Abbatecola and G. Paolisso, “Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Trial,” Diabetes Care, vol. 32, no. 8, p. e102, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. D. G. Bruce, W. A. Davis, G. P. Casey et al., “Predictors of cognitive impairment and dementia in older people with diabetes,” Diabetologia, vol. 51, no. 2, pp. 241–248, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. M. Tiehuis, Y. van der Graaf, F. L. Visseren et al., “Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease,” Stroke, vol. 39, no. 5, pp. 1600–1603, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. H. Shalev, Y. Serlin, and A. Friedman, “Breaching the blood-brain barrier as a gate to psychiatric disorder,” Cardiovascular Psychiatry and Neurology, vol. 2009, Article ID 278531, 7 pages, 2009. View at Google Scholar
  12. P. N. Surampudi, J. John-Kalarickal, and V. A. Fonseca, “Emerging concepts in the pathophysiology of type 2 diabetes mellitus,” Mount Sinai Journal of Medicine, vol. 76, no. 3, pp. 216–226, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. Y. Lin and Z. Sun, “Current views on type 2 diabetes,” Journal of Endocrinology, vol. 204, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. K. E. Wellen and G. S. Hotamisligil, “Obesity-induced inflammatory changes in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1785–1788, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. H. Golden, M. Lazo, M. Carnethon et al., “Examining a bidirectional association between depressive symptoms and diabetes,” Journal of the American Medical Association, vol. 299, no. 23, pp. 2751–2759, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. B. McGill, “Improving microvascular outcomes in patients with diabetes through management of hypertension,” Postgraduate Medicine, vol. 121, no. 2, pp. 89–101, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. P. M. Ridker, “Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity,” Nutrition Reviews, vol. 65, no. 12, pp. S253–S259, 2007. View at Google Scholar · View at Scopus
  20. P. Geraldes and G. L. King, “Activation of protein kinase C isoforms and its impact on diabetic complications,” Circulation Research, vol. 106, no. 8, pp. 1319–1331, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. S. I. Yamagishi and T. Imaizumi, “Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy,” Current Pharmaceutical Design, vol. 11, no. 18, pp. 2279–2299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Ristow, “Neurodegenetive disorders associated with diabetes mellitus,” Journal of Molecular Medicine, vol. 82, no. 8, pp. 510–529, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. B. T. Hawkins and T. P. Davis, “The blood-brain barrier/neurovascular unit in health and disease,” Pharmacological Reviews, vol. 57, no. 2, pp. 173–185, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. N. J. Abbott, L. Ronnback, and E. Hansson, “Astrocyte-endothelial interactions at the blood-brain barrier,” Nature Reviews Neuroscience, vol. 7, no. 1, pp. 41–53, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. B. V. Zlokovic, “The blood-brain barrier in health and chronic neurodegenerative disorders,” Neuron, vol. 57, no. 2, pp. 178–201, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. P. S. Tofts, G. Brix, D. L. Buckley et al., “Estimating kinetic parameters from dynamic contrast-enhanced T-weighted MRI of a diffusable tracer: standardized quantities and symbols,” Journal of Magnetic Resonance Imaging, vol. 10, no. 3, pp. 223–232, 1999. View at Google Scholar
  27. G. Zaharchuk, “Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability,” American Journal of Neuroradiology, vol. 28, no. 10, pp. 1850–1858, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. O. Tomkins, I. Shelef, I. Kaizerman et al., “Blood-brain barrier disruption in post-traumatic epilepsy,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 7, pp. 774–777, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. N. Marchi, P. Rasmussen, M. Kapural et al., “Peripheral markers of brain damage and blood-brain barrier dysfunction,” Restorative Neurology and Neuroscience, vol. 21, no. 3-4, pp. 109–121, 2003. View at Google Scholar · View at Scopus
  30. S. Nag, R. Venugopalan, and D. J. Stewart, “Increased caveolin-1 expression precedes decreased expression of occludin and claudin-5 during blood-brain barrier breakdown,” Acta Neuropathologica, vol. 114, no. 5, pp. 459–469, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. S. Nag, J. L. Manias, and D. J. Stewart, “Expression of endothelial phosphorylated caveolin-1 is increased in brain injury,” Neuropathology and Applied Neurobiology, vol. 35, no. 4, pp. 417–426, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J. Zhao, A. N. Moore, J. B. Redell, and P. K. Dash, “Enhancing expression of Nrf2-driven genes protects the blood-brain barrier after brain injury,” Journal of Neuroscience, vol. 27, no. 38, pp. 10240–10248, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. D. Yeung, J. L. Manias, D. J. Stewart, and S. Nag, “Decreased junctional adhesion molecule-A expression during blood-brain barrier breakdown,” Acta Neuropathologica, vol. 115, no. 6, pp. 635–642, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. T. Higashida, C. W. Kreipke, J. A. Rafols et al., “The role of hypoxia-inducible factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury,” Journal of Neurosurgery, vol. 114, no. 1, pp. 92–101, 2011. View at Google Scholar
  35. P. Dore-Duffy, C. Owen, R. Balabanov, S. Murphy, T. Beaumont, and J. A. Rafols, “Pericyte migration from the vascular wall in response to traumatic brain injury,” Microvascular Research, vol. 60, no. 1, pp. 55–69, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. Nag, J. L. Takahashi, and D. W. Kilty, “Role of vascular endothelial growth factor in blood-brain barrier breakdown and angiogenesis in brain trauma,” Journal of Neuropathology and Experimental Neurology, vol. 56, no. 8, pp. 912–921, 1997. View at Google Scholar · View at Scopus
  37. F. Marceau and D. Regoli, “Bradykinin receptor ligands: therapeutic perspectives,” Nature Reviews Drug Discovery, vol. 3, no. 10, pp. 845–852, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. L. M. F. Leeb-Lundberg, “Bradykinin specificity and signaling at GPR100 and B kinin receptors,” British Journal of Pharmacology, vol. 143, no. 8, pp. 931–932, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. M. Schwaninger, S. Sallmann, N. Petersen et al., “Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear factor-κB,” Journal of Neurochemistry, vol. 73, no. 4, pp. 1461–1466, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. M. A. Deli, L. Descamps, M. P. Dehouck et al., “Exposure of tumor necrosis factor-α to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin,” Journal of Neuroscience Research, vol. 41, no. 6, pp. 717–726, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. N. Didier, I. A. Romero, C. Créminon, A. Wijkhuisen, J. Grassi, and A. Mabondzo, “Secretion of interleukin-1β by astrocytes mediates endothelin-1 and tumour necrosis factor-α effects on human brain microvascular endothelial cell permeability,” Journal of Neurochemistry, vol. 86, no. 1, pp. 246–254, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. J. D. Huber, R. D. Egleton, and T. P. Davis, “Molecular physiology and pathophysiology of tight junctions in the blood -brain barrier,” Trends in Neurosciences, vol. 24, no. 12, pp. 719–725, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Gursoy-Ozdemir, J. Qiu, N. Matsuoka et al., “Cortical spreading depression activates and upregulates MMP-9,” Journal of Clinical Investigation, vol. 113, no. 10, pp. 1447–1455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. W. G. Mayhan, “Effect of diabetes mellitus on disruption of the blood-brain barrier during acute hypertension,” Brain Research, vol. 534, no. 1-2, pp. 106–110, 1990. View at Publisher · View at Google Scholar · View at Scopus
  45. M. H. Horani and A. D. Mooradian, “Effect of diabetes on the blood brain barrier,” Current Pharmaceutical Design, vol. 9, no. 10, pp. 833–840, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Dai, G. F. J. M. Vrensen, and R. O. Schlingemann, “Blood-brain barrier integrity is unaltered in human brain cortex with diabetes mellitus,” Brain Research, vol. 954, no. 2, pp. 311–316, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. W. D. Dietrich, O. Alonso, and R. Busto, “Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats,” Stroke, vol. 24, no. 1, pp. 111–116, 1993. View at Google Scholar · View at Scopus
  48. H. Kamada, F. Yu, C. Nito, and P. H. Chan, “Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction,” Stroke, vol. 38, no. 3, pp. 1044–1049, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. J. M. Starr, J. M. Wardlaw, K. Ferguson, A. MacLullich, I. J. Deary, and I. Marshall, “Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 1, pp. 70–76, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. M. R. Hovsepyan, M. J. Haas, A. S. Boyajyan et al., “Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus,” Neuroscience Letters, vol. 369, no. 3, pp. 224–227, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. S. J. Vannucci, E. M. Gibbs, and I. A. Simpson, “Glucose utilization and glucose transporter proteins GLUT-1 and GLUT-3 in brains of diabetic (db/db) mice,” American Journal of Physiology, vol. 272, no. 2, pp. E267–E274, 1997. View at Google Scholar · View at Scopus
  52. W. M. Pardridge, D. Triguero, and C. R. Farrell, “Downregulation of blood-brain barrier glucose transporter in experimental diabetes,” Diabetes, vol. 39, no. 9, pp. 1040–1044, 1990. View at Google Scholar · View at Scopus
  53. S. Pennathur and J. W. Heinecke, “Oxidative stress and endothelial dysfunction in vascular disease,” Current Diabetes Reports, vol. 7, no. 4, pp. 257–264, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. V. B. Schrauwen-Hinderling, M. Roden, M. E. Kooi, M. K. C. Hesselink, and P. Schrauwen, “Muscular mitochondrial dysfunction and type 2 diabetes mellitus,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 10, no. 6, pp. 698–703, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. Y. Lin, M. W. Rajala, J. P. Berger, D. E. Moller, N. Barzilai, and P. E. Scherer, “Hyperglycemia-induced production of acute phase reactants in adipose tissue,” Journal of Biological Chemistry, vol. 276, no. 45, pp. 42077–42083, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. C. L. Scott, “Diagnosis, prevention, and intervention for the metabolic syndrome,” American Journal of Cardiology, vol. 92, no. 1, pp. 35i–42i, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Meerwaldt, C. J. Zeebregts, G. Navis, J. L. Hillebrands, J. D. Lefrandt, and A. J. Smit, “Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis,” American Journal of Kidney Diseases, vol. 53, no. 1, pp. 138–150, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. R. Piga, Y. Naito, S. Kokura, O. Handa, and T. Yoshikawa, “Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells,” Atherosclerosis, vol. 193, no. 2, pp. 328–334, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. R. Klein, B. E. K. Klein, S. E. Moss, M. D. Davis, and D. L. DeMets, “Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy,” Journal of the American Medical Association, vol. 260, no. 19, pp. 2864–2871, 1988. View at Google Scholar · View at Scopus
  60. S. Vitale, M. G. Maguire, R. P. Murphy et al., “Clinically significant macular edema in type I diabetes: incidence and risk factors,” Ophthalmology, vol. 102, no. 8, pp. 1170–1176, 1995. View at Google Scholar · View at Scopus
  61. R. Klein, B. E. K. Klein, S. E. Moss, and K. J. Cruickshanks, “The wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14- year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes,” Ophthalmology, vol. 105, no. 10, pp. 1801–1815, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Klein, B. E. K. Klein, and S. E. Moss, “The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema,” Ophthalmology, vol. 91, no. 12, pp. 1464–1474, 1984. View at Google Scholar · View at Scopus
  63. C. H. Meyer, “Current treatment approaches in diabetic macular edema,” Ophthalmologica, vol. 221, no. 2, pp. 118–131, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. U. Chakravarthy, R. G. Hayes, A. W. Stitt, E. McAuley, and D. B. Archer, “Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products,” Diabetes, vol. 47, no. 6, pp. 945–952, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Lu, M. Kuroki, S. Amano et al., “Advanced glycation end products increase retinal vascular endothelial growth factor expression,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1219–1224, 1998. View at Google Scholar · View at Scopus
  66. T. A. Ciulla, A. Harris, P. Latkany et al., “Ocular perfusion abnormalities in diabetes,” Acta Ophthalmologica Scandinavica, vol. 80, no. 5, pp. 468–477, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Paget, M. Lecomte, D. Ruggiero, N. Wiernsperger, and M. Lagarde, “Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products,” Free Radical Biology and Medicine, vol. 25, no. 1, pp. 121–129, 1998. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Miyamoto and Y. Ogura, “Pathogenetic potential of leukocytes in diabetic retinopathy,” Seminars in Ophthalmology, vol. 14, no. 4, pp. 233–239, 1999. View at Google Scholar · View at Scopus
  69. L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994. View at Publisher · View at Google Scholar · View at Scopus
  70. J. W. Miller, A. P. Adamis, and L. P. Aiello, “Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy,” Diabetes/Metabolism Reviews, vol. 13, no. 1, pp. 37–50, 1997. View at Publisher · View at Google Scholar · View at Scopus
  71. J. D. Huber, “Diabetes, cognitive function, and the blood-brain barrier,” Current Pharmaceutical Design, vol. 14, no. 16, pp. 1594–1600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. O. Tomkins, I. Shelef, I. Kaizerman et al., “Blood-brain barrier disruption in post-traumatic epilepsy,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 7, pp. 774–777, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. O. Prager, Y. Chassidim, C. Klein, H. Levi, I. Shelef, and A. Friedman, “Dynamic in vivo imaging of cerebral blood flow and blood-brain barrier permeability,” NeuroImage, vol. 49, no. 1, pp. 337–344, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. N. Cheung, T. Mosley, A. Islam et al., “Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study,” Brain, vol. 133, no. 7, pp. 1987–1993, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. I. Skoog, A. Wallin, P. Fredman et al., “A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia,” Neurology, vol. 50, no. 4, pp. 966–971, 1998. View at Google Scholar · View at Scopus
  76. P. Gudmundsson, I. Skoog, M. Waern et al., “The relationship between cerebrospinal fluid biomarkers and depression in elderly women,” American Journal of Geriatric Psychiatry, vol. 15, no. 10, pp. 832–838, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. N. Muller and M. Ackenheil, “Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology,” Schizophrenia Research, vol. 14, no. 3, pp. 223–228, 1995. View at Publisher · View at Google Scholar · View at Scopus
  78. M. J. Schwarz, M. Ackenheil, M. Riedel, and N. Müller, “Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia,” Neuroscience Letters, vol. 253, no. 3, pp. 201–203, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. R. D. Bell and B. V. Zlokovic, “Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease,” Acta Neuropathologica, vol. 118, no. 1, pp. 103–113, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. M. Rothermundt, G. Ponath, T. Glaser, G. Hetzel, and V. Arolt, “S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia,” Neuropsychopharmacology, vol. 29, no. 5, pp. 1004–1011, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. M. L. Schroeter, H. Abdul-Khaliq, M. Krebs, A. Diefenbacher, and I. E. Blasig, “Serum markers support disease-specific glial pathology in major depression,” Journal of Affective Disorders, vol. 111, no. 2-3, pp. 271–280, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. M. De Groot, R. Anderson, K. E. Freedland, R. E. Clouse, and P. J. Lustman, “Association of depression and diabetes complications: a meta-analysis,” Psychosomatic Medicine, vol. 63, no. 4, pp. 619–630, 2001. View at Google Scholar · View at Scopus
  83. R. J. Anderson, K. E. Freedland, R. E. Clouse, and P. J. Lustman, “The prevalence of comorbid depression in adults with diabetes: a meta-analysis,” Diabetes Care, vol. 24, no. 6, pp. 1069–1078, 2001. View at Google Scholar · View at Scopus
  84. S. H. Saydah, F. L. Brancati, S. H. Golden, J. Fradkin, and M. I. Harris, “Depressive symptoms and the risk of type 2 diabetes mellitus in a US sample,” Diabetes/Metabolism Research and Reviews, vol. 19, no. 3, pp. 202–208, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. S. Ali, M. A. Stone, J. L. Peters, M. J. Davies, and K. Khunti, “The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis,” Diabetic Medicine, vol. 23, no. 11, pp. 1165–1173, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. T. Cukierman-Yaffe, H. C. Gerstein, J. D. Williamson et al., “Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular rIsk factors the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial,” Diabetes Care, vol. 32, no. 2, pp. 221–226, 2009. View at Publisher · View at Google Scholar · View at PubMed
  87. S. D. Yan, X. Chen, J. Fu et al., “RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease,” Nature, vol. 382, no. 6593, pp. 685–691, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. K. Horie, T. Miyata, T. Yasuda et al., “Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons,” Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 327–332, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. H. Vlassara, R. Bucala, and L. Striker, “Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging,” Laboratory Investigation, vol. 70, no. 2, pp. 138–151, 1994. View at Google Scholar · View at Scopus
  90. E. W. Gregg, K. Yaffe, J. A. Cauley et al., “Is diabetes associated with cognitive impairment and cognitive decline among older women?” Archives of Internal Medicine, vol. 160, no. 2, pp. 174–180, 2000. View at Google Scholar
  91. K. Yaffe, T. Blackwell, A. M. Kanaya, N. Davidowitz, E. Barrett-Connor, and K. Krueger, “Diabetes, impaired fasting glucose, and development of cognitive impairment in older women,” Neurology, vol. 63, no. 4, pp. 658–663, 2004. View at Google Scholar · View at Scopus
  92. K. V. Allen, B. M. Frier, and M. W. J. Strachan, “The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 169–175, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. C. E. Lloyd, P. H. Dyert, and A. H. Barnett, “Prevalence of symptoms of depression and anxiety in a diabetes clinic population,” Diabetic Medicine, vol. 17, no. 3, pp. 198–202, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. R. J. Anderson, M. De Groot, A. B. Grigsby et al., “Anxiety and poor glycemic control: a meta-analytic review of the literature,” International Journal of Psychiatry in Medicine, vol. 32, no. 3, pp. 235–247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Gardner and R. G. Boles, “Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders,” Progress in Neuro-Psychopharmacology and Biological Psychiatry. In press. View at Publisher · View at Google Scholar · View at PubMed
  96. Y. Dowlati, N. Herrmann, W. Swardfager et al., “A meta-analysis of cytokines in major depression,” Biological Psychiatry, vol. 67, no. 5, pp. 446–457, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. M. Maes, R. Yirmyia, J. Noraberg et al., “The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression,” Metabolic Brain Disease, vol. 24, no. 1, pp. 27–53, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. E. M. Sternberg, “Neural-immune interactions in health and disease,” Journal of Clinical Investigation, vol. 100, no. 11, pp. 2641–2647, 1997. View at Google Scholar · View at Scopus
  99. C. Woiciechowsky, K. Asadullah, D. Nestler et al., “Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury,” Nature Medicine, vol. 4, no. 7, pp. 808–813, 1998. View at Publisher · View at Google Scholar · View at Scopus
  100. N. Vila, J. Castillo, A. Dávalos, and A. Chamorro, “Proinflammatory cytokines and early neurological worsening in ischemic stroke,” Stroke, vol. 31, no. 10, pp. 2325–2329, 2000. View at Google Scholar · View at Scopus
  101. J. C. O'Connor, D. R. Johnson, and G. G. Freund, “Psychoneuroimmune implications of type 2 diabetes: redux,” Immunology and Allergy Clinics of North America, vol. 29, no. 2, pp. 339–358, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. C. L. Raison, L. Capuron, and A. H. Miller, “Cytokines sing the blues: inflammation and the pathogenesis of depression,” Trends in Immunology, vol. 27, no. 1, pp. 24–31, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. A. J. Thomas, S. Davis, C. Morris, E. Jackson, R. Harrison, and J. T. O'Brien, “Increase in interleukin-1β in late-life depression,” American Journal of Psychiatry, vol. 162, no. 1, pp. 175–177, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. S. Alesci, P. E. Martinez, S. Kelkar et al., “Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 2522–2530, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. C. A. Turner, H. Akil, S. J. Watson, and S. J. Evans, “The fibroblast growth factor system and mood disorders,” Biological Psychiatry, vol. 59, no. 12, pp. 1128–1135, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. H. D. Schmidt and R. S. Duman, “The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior,” Behavioural Pharmacology, vol. 18, no. 5-6, pp. 391–418, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. C. Sandi and R. Bisaz, “A model for the involvement of neural cell adhesion molecules in stress-related mood disorders,” Neuroendocrinology, vol. 85, no. 3, pp. 158–176, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. M. Maes, E. Bosmans, H. Y. Meltzer, S. Scharpe, and E. Suy, “Interleukin-1β: a putative mediator of HPA axis hyperactivity in major depression?” American Journal of Psychiatry, vol. 150, no. 8, pp. 1189–1193, 1993. View at Google Scholar · View at Scopus
  109. I. Goshen, T. Kreisel, O. Ben-Menachem-Zidon et al., “Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression,” Molecular Psychiatry, vol. 13, no. 7, pp. 717–728, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. M. Maes, R. Verkerk, S. Bonaccorso, W. Ombelet, E. Bosmans, and S. Scharpé, “Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation,” Life Sciences, vol. 71, no. 16, pp. 1837–1848, 2002. View at Publisher · View at Google Scholar
  111. M. C. Wichers, G. Kenis, G. H. Koek, G. Robaeys, N. A. Nicolson, and M. Maes, “Interferon-α-induced depressive symptoms are related to changes in the cytokine network but not to cortisol,” Journal of Psychosomatic Research, vol. 62, no. 2, pp. 207–214, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. R. Dantzer, J. C. O'Connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, “From inflammation to sickness and depression: when the immune system subjugates the brain,” Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46–56, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. N. Müller and M. J. Schwarz, “The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression,” Molecular Psychiatry, vol. 12, no. 11, pp. 988–1000, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. E. Fedele and A. C. Foster, “An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum,” Neuroscience, vol. 52, no. 4, pp. 911–917, 1993. View at Publisher · View at Google Scholar · View at Scopus
  115. V. H. Perry, “The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease,” Brain, Behavior, and Immunity, vol. 18, no. 5, pp. 407–413, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. S. M. Allan and N. J. Rothwell, “Cytokines and acute neurodegeneration,” Nature Reviews Neuroscience, vol. 2, no. 10, pp. 734–744, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. S. Craft, “The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged,” Archives of Neurology, vol. 66, no. 3, pp. 300–305, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. J.-S. Roriz, T. M. Sá-Roriz, I. Rosset et al., “(Pre)diabetes, brain aging, and cognition,” Biochimica et Biophysica Acta, vol. 1792, no. 5, pp. 432–443, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  119. B. Segura, M. A. Jurado, N. Freixenet, C. Albuin, J. Muniesa, and C. Junqué, “Mental slowness and executive dysfunctions in patients with metabolic syndrome,” Neuroscience Letters, vol. 462, no. 1, pp. 49–53, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. K. Martinowich, H. Manji, and B. Lu, “New insights into BDNF function in depression and anxiety,” Nature Neuroscience, vol. 10, no. 9, pp. 1089–1093, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. E. Chemerinski and S. R. Levine, “Neuropsychiatric disorders following vascular brain injury,” Mount Sinai Journal of Medicine, vol. 73, no. 7, pp. 1006–1014, 2006. View at Google Scholar · View at Scopus
  122. K. M. Dunn and M. T. Nelson, “Potassium channels and neurovascular coupling,” Circulation Journal, vol. 74, no. 4, pp. 608–616, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. R. F. Haseloff, I. E. Blasig, H. C. Bauer, and H. Bauer, “In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro,” Cellular and Molecular Neurobiology, vol. 25, no. 1, pp. 25–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. A. Friedman, D. Kaufer, and U. Heinemann, “Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy,” Epilepsy Research, vol. 85, no. 2-3, pp. 142–149, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. L. P. Cacheaux, S. Ivens, Y. David et al., “Transcriptome profiling reveals TGF-β signaling involvement in epileptogenesis,” Journal of Neuroscience, vol. 29, no. 28, pp. 8927–8935, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. S. Ivens, D. Kaufer, L. P. Flores et al., “TGF-β receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis,” Brain, vol. 130, no. 2, pp. 535–547, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. M. Zonta, M. C. Angulo, S. Gobbo et al., “Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation,” Nature Neuroscience, vol. 6, no. 1, pp. 43–50, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. H. R. Parri and V. Crunelli, “The role of Ca2+ in the generation of spontaneous astrocytic Ca2+ oscillations,” Neuroscience, vol. 120, no. 4, pp. 979–992, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. D. L. Price, J. W. Ludwig, H. Mi, T. L. Schwarz, and M. H. Ellisman, “Distribution of rSlo Ca2+-activated K+ channels in rat astrocyte perivascular endfeet,” Brain Research, vol. 956, no. 2, pp. 183–193, 2002. View at Publisher · View at Google Scholar · View at Scopus
  130. H. J. Knot, P. A. Zimmermann, and M. T. Nelson, “Extracellular K+-induced hyperpolarizations and dilatations of rat coronary and cerebral arteries involve inward rectifier K+ channels,” Journal of Physiology, vol. 492, no. 2, pp. 419–430, 1996. View at Google Scholar · View at Scopus
  131. J. A. Filosa, A. D. Bonev, S. V. Straub et al., “Local potassium signaling couples neuronal activity to vasodilation in the brain,” Nature Neuroscience, vol. 9, no. 11, pp. 1397–1403, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. G. Carmignoto and M. Gómez-Gonzalo, “The contribution of astrocyte signalling to neurovascular coupling,” Brain Research Reviews, vol. 63, no. 1-2, pp. 138–148, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. G. Perea and A. Araque, “Astrocytes potentiate transmitter release at single hippocampal synapses,” Science, vol. 317, no. 5841, pp. 1083–1086, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. P. Jourdain, L. H. Bergersen, K. Bhaukaurally et al., “Glutamate exocytosis from astrocytes controls synaptic strength,” Nature Neuroscience, vol. 10, no. 3, pp. 331–339, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. S. Fleminger, “Long-term psychiatric disorders after traumatic brain injury,” European Journal of Anaesthesiology, vol. 25, supplement 42, pp. 123–130, 2008. View at Publisher · View at Google Scholar · View at PubMed
  136. D. F. Guerreiro, R. Navarro, M. Silva, M. Carvalho, and C. Gois, “Psychosis secondary to traumatic brain injury,” Brain Injury, vol. 23, no. 4, pp. 358–361, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus